GILD Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
7.8B
+12.1%
7.0B
-12.2%
7.9B
+2.0%
7.8B
+9.7%
7.1B
Cost of Revenue
1.6B
+9.3%
1.4B
-11.0%
1.6B
+3.5%
1.6B
+4.5%
1.5B
Gross Profit
6.2B
+12.9%
5.5B
-12.5%
6.3B
+1.6%
6.2B
+11.1%
5.6B
Operating Expenses
16.6B
+467.2%
2.9B
-32.1%
4.3B
+50.3%
2.9B
-7.5%
3.1B
R&D
12.9B
+843.7%
1.4B
-13.4%
1.6B
+17.7%
1.3B
-13.3%
1.6B
SG&A
1.9B
+32.4%
1.5B
-19.1%
1.8B
+32.2%
1.4B
-0.6%
1.4B
Operating Income
-10394000000
-502.1%
2.6B
+30.3%
2.0B
-40.4%
3.3B
+34.5%
2.5B
EBITDA
-7946000000
-335.0%
3.4B
-6.3%
3.6B
-13.7%
4.2B
+24.7%
3.4B
Net Income
-10496000000
-619.3%
2.0B
-7.4%
2.2B
-28.5%
3.1B
+55.6%
2.0B
EPS (Basic)
$-8.45
-618.4%
$1.63
-7.4%
$1.76
-28.5%
$2.46
+56.7%
$1.57
EPS (Diluted)
$-8.45
-624.8%
$1.61
-7.5%
$1.74
-28.4%
$2.43
+55.8%
$1.56
Shares (Diluted)
1.2B
-0.9%
1.3B
+0.2%
1.3B
-0.2%
1.3B
-0.1%
1.3B
Gilead Sciences (GILD) โ€” Financials